Skip to main content
Clinical Trials/CTRI/2024/03/063481
CTRI/2024/03/063481Not yet recruitingPhase 3

Efficacy and Safety of Anticoagulation in patients with Digital Gangrene and an underlying Connective Tissue Disease - NI

Department of Clinical Immunology & Rheumatology0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Patients with digital gangrene of duration less than or equal to 1 month, defined as bluish blackish
  • discoloration of any digit, including pre-gangrenous changes in the form of intense pain, pallor
  • and/or dusky colour change of digits and delayed capillary refill time.
  • 2. Patients with a diagnosis of Connective tissue disorder (CTD) as per latest standard
  • diagnostic/classification criteria

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Department of Clinical Immunology & Rheumatology

Similar Trials